On October 7, 2025, MannKind Corp completed the acquisition of scPharmaceuticals, having paid approximately $296.5 million for the deal. The acquisition included a tender offer that received valid bids for 73.47% of scPharma's shares, which will allow MannKind to expand its product offerings.